



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



**Australian Securities Exchange Limited  
Companies Announcements Office  
SYDNEY**

**25 June, 2012**

### **Market Update on Suspension of Fully Paid Shares**

**SYDNEY Australia 25 June June 2012:** Australian immunotherapeutics business, Bioxyne Limited (ASX: BXN), wishes to advise that its Fully Paid Ordinary shares will remain in suspension until the results of the clinical trials are fully assessed.

The Company has received both the initial results and further very detailed analyses of the data. The analysis is ongoing and now requires professional validation. The Company believes that it will be in a position to release a detailed announcement after this review on Wednesday, 27 June 2012.

David Radford

Managing Director



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



## About Bioxyne

Bioxyne Limited (ASX:BNE) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit [www.bioxyne.com](http://www.bioxyne.com)